Capital Flow Monitor · Sponsors · CIK 1829522
Antlia Bioscience, Inc.
1281 HYMETTUS AVE, ENCINITAS, CA, 92024 · 619-990-0290
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$20.0M
Sold
$6.0M
% sold
30.0%
Investors
3
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | D ·current | 506(b) | $20.0M | $6.0M | 30.0% | 3 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Ankit Mahadevia — Executive Officer / Director, Encinitas, CA
-
Ben Auspitz — Director, Encinitas, CA
1 other raise
- Prana Therapies, Inc. $40.2M of $40.2M · 100.0%
-
Brian Laurence Johnson — Executive Officer / Director, Encinitas, CA
1 other raise
- Caradon Therapeutics, Inc. $559K of $900K · 62.1%
- Carlos Garcia Echeverria — Director, Encinitas, CA
-
Nihal Sinha — Director, Encinitas, CA
1 other raise
- CHARM Therapeutics Inc. $17.3M of $80.1M · 21.6%
- Martin Taylor — Director, Encinitas, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.